 |
57 Diseases |  |
1 Trial |
|
1 Trial |  |
260 News |  |
| «1234» |
- | evofosfamide (TH 302) / Molecular Templates
Journal: Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma. (Pubmed Central) - Sep 30, 2017
Therapeutic strategies which specifically target interstrand crosslink repair can therefore be helpful in patients with harmful mutations. We describe two patients with advanced ovarian cancer and deleterious BRCA1 mutations who were treated with TH-302, a hypoxia-activated alkylating agent.
- | evofosfamide (TH 302) / Molecular Templates
Journal: Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. (Pubmed Central) - Sep 21, 2017
P3
We describe two patients with advanced ovarian cancer and deleterious BRCA1 mutations who were treated with TH-302, a hypoxia-activated alkylating agent. The addition of evofosfamide to doxorubicin as first-line therapy did not improve overall survival compared with single-drug doxorubicin in patients with locally advanced, unresectable, or metastatic soft-tissue sarcomas and so this combination cannot be recommended in this setting.
- | Votrient (pazopanib) / Novartis, BeiGene, evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial completion, Trial primary completion date, Metastases: Dose Escalation Study of Pazopanib Plus TH-302 (clinicaltrials.gov) - Sep 1, 2017
P1, N=50, Completed, Sponsor: Herbert Hurwitz, MD
The addition of evofosfamide to doxorubicin as first-line therapy did not improve overall survival compared with single-drug doxorubicin in patients with locally advanced, unresectable, or metastatic soft-tissue sarcomas and so this combination cannot be recommended in this setting. Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Feb 2013
- | Avastin (bevacizumab) / Roche, evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment closed, Combination therapy: TH-302 in Combination With Bevacizumab for Glioblastoma (clinicaltrials.gov) - Aug 9, 2017
P2, N=35, Active, not recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Feb 2013 Recruiting --> Active, not recruiting
- | evofosfamide (TH 302) / Molecular Templates
Journal: A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model. (Pubmed Central) - Aug 6, 2017
The improvement in tumor response when evofosfamide is combined with RT supports the hypothesis that hypoxia is a cause of radioresistance in high dose RT for pancreatic cancer. Assessing the efficacy and safety of stereotactic radiation treatment and evofosfamide is warranted in patients with locally advanced pancreatic cancer.
- | evofosfamide (TH 302) / Molecular Templates
Journal: A Phase I Study of Evofosfamide, an Investigational Hypoxia-Activated Prodrug, in Patients with Advanced Leukemia. (Pubmed Central) - Jul 19, 2017
P1
Evofosfamide has shown limited activity in heavily pretreated leukemia patients. Further evaluation investigating evofosfamide in combination with cytotoxic or demethylating agents is warranted.
- | Votrient (pazopanib) / Novartis, evofosfamide (TH 302) / Molecular Templates
Journal: Phase I study of pazopanib plus TH-302 in advanced solid tumors. (Pubmed Central) - Jun 15, 2017
The RPTD for this novel combination is pazopanib 800 mg daily on days 1-28 plus TH-302 340 mg/m(2) on days 1, 8 and 15 of each 28-day cycle. Preliminary activity was seen in treatment-refractory cancers and supports potential value of co-targeting tumor angiogenesis and tumor hypoxia.
- ||| evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment open, Combination therapy, Metastases: Immunotherapy Study of Evofosfamide in Combination With Ipilimumab (clinicaltrials.gov) - May 12, 2017
P1, N=69, Recruiting, Sponsor: Threshold Pharmaceuticals
Preliminary activity was seen in treatment-refractory cancers and supports potential value of co-targeting tumor angiogenesis and tumor hypoxia. Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche, evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial primary completion date, Combination therapy: TH-302 in Combination With Bevacizumab for Glioblastoma (clinicaltrials.gov) - Apr 25, 2017
P2, N=33, Recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2017 --> Jul 2017
- ||| evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
New P1 trial, Combination therapy, Metastases: Immunotherapy Study of Evofosfamide in Combination With Ipilimumab (clinicaltrials.gov) - Mar 31, 2017
P1, N=69, Not yet recruiting, Sponsor: Threshold Pharmaceuticals
- | Sutent (sunitinib) / Pfizer, evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment open, Trial primary completion date, Combination therapy, Metastases: SUNEVO: A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours (clinicaltrials.gov) - Mar 13, 2017
P2, N=43, Recruiting, Sponsor: Grupo Espanol de Tumores Neuroendocrinos
Trial primary completion date: Feb 2017 --> Jul 2017 Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2017 --> Jan 2019
- Votrient (pazopanib) / Novartis, BeiGene, evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial primary completion date, Metastases: Dose Escalation Study of Pazopanib Plus TH-302 (clinicaltrials.gov) - Feb 11, 2017
P1, N=50, Active, not recruiting, Sponsor: Herbert Hurwitz, MD
Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2017 --> Jan 2019 Trial primary completion date: Dec 2016 --> Jun 2017
- Avastin (bevacizumab) / Roche, evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial completion, Trial primary completion date: Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab (clinicaltrials.gov) - Oct 26, 2016
P2, N=29, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
Trial primary completion date: Dec 2016 --> Jun 2017 Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Oct 2015
- | Sutent (sunitinib) / Pfizer, evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment closed, Combination therapy, Metastases: SUNEVO: A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours (clinicaltrials.gov) - Aug 11, 2016
P2, N=43, Active, not recruiting, Sponsor: Grupo Espanol de Tumores Neuroendocrinos
Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Oct 2015 Recruiting --> Active, not recruiting
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Phase classification, Trial primary completion date, Surgery, Metastases: Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 20, 2016
P2, N=48, Suspended, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting Phase classification: P1/2 --> P2 | Trial primary completion date: Jan 2016 --> Jan 2018
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment change, Trial termination, Trial primary completion date, Combination therapy, Metastases: EMR200592-008: A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 18, 2016
P2, N=6, Terminated, Sponsor: Merck KGaA
Phase classification: P1/2 --> P2 | Trial primary completion date: Jan 2016 --> Jan 2018 N=46 --> 6 | Recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Jan 2016; Sponsor's decision due to negative result of Phase 3 study TH-CR-406/SARC021
- ||||||| evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial completion, Combination therapy, Metastases: MAESTRO: Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jun 11, 2016
P3, N=694, Completed, Sponsor: EMD Serono
N=46 --> 6 | Recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Jan 2016; Sponsor's decision due to negative result of Phase 3 study TH-CR-406/SARC021 Active, not recruiting --> Completed
- | evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment change, Trial initiation date, Trial termination, Trial primary completion date, Combination therapy, Metastases: Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 5, 2016
P2, N=265, Terminated, Sponsor: Threshold Pharmaceuticals
Active, not recruiting --> Completed N=440 --> 265 | Initiation date: Mar 2014 --> Jun 2014 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Apr 2016; At the interim analysis, the futility boundary was not met and the study was stopped due to insufficient efficacy.
- ||||||| evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial completion, Trial primary completion date, Combination therapy, Metastases: TH-CR-406: A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 2, 2016
P3, N=640, Completed, Sponsor: Threshold Pharmaceuticals
N=440 --> 265 | Initiation date: Mar 2014 --> Jun 2014 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Apr 2016; At the interim analysis, the futility boundary was not met and the study was stopped due to insufficient efficacy. Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Dec 2015
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment closed, Metastases: A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 2, 2016
P1, N=40, Active, not recruiting, Sponsor: Threshold Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Dec 2015 Recruiting --> Active, not recruiting
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial completion, Metastases: EMR200592-007: A Phase 1 TH-302 Mass Balance Trial (clinicaltrials.gov) - Apr 21, 2016
P1, N=10, Completed, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment change, Trial withdrawal, Trial primary completion date, Combination therapy: Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer. (clinicaltrials.gov) - Apr 21, 2016
P1, N=0, Withdrawn, Sponsor: Maastricht Radiation Oncology
Active, not recruiting --> Completed N=18 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Apr 2016
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment change, Trial termination, Combination therapy, Metastases: EMR200592-006: Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer (clinicaltrials.gov) - Mar 30, 2016
P1, N=19, Terminated, Sponsor: EMD Serono
N=18 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Apr 2016 N=48 --> 19 | Recruiting --> Terminated; The trial has been terminated earlier following the company decision to discontinue the clinical development of Evofosfamide
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
New trial: SARC021C: A Continuation Study of TH-CR-406/SARC021 (clinicaltrials.gov) - Mar 18, 2016
P=N/A, N=0, No Longer Available, Sponsor: Sarcoma Alliance for Research through Collaboration
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial suspension, Surgery, Metastases: Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jan 25, 2016
P1/2, N=48, Suspended, Sponsor: Alliance for Clinical Trials in Oncology
N=48 --> 19 | Recruiting --> Terminated; The trial has been terminated earlier following the company decision to discontinue the clinical development of Evofosfamide Recruiting --> Suspended
- ||| evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment closed, Combination therapy, Metastases: Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 22, 2016
P2, N=440, Active, not recruiting, Sponsor: Threshold Pharmaceuticals
Recruiting --> Suspended Recruiting --> Active, not recruiting
- ||| evofosfamide (TH 302) / Molecular Templates, ImmunoGenesis
Clinical: Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 7, 2016
P1/2, N=98, Active, not recruiting, Sponsor: Threshold Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=60 --> 98 | Trial primary completion date: Jun 2015 --> Sep 2016
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial primary completion date, Combination therapy: Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer. (clinicaltrials.gov) - Dec 5, 2015
P1, N=18, Not yet recruiting, Sponsor: Maastricht Radiation Oncology
Recruiting --> Active, not recruiting | N=60 --> 98 | Trial primary completion date: Jun 2015 --> Sep 2016 Trial primary completion date: Dec 2016 --> Dec 2017
- | evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial completion, Combination therapy, Monotherapy, IO biomarker, Metastases: EMR200592-002: A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer (clinicaltrials.gov) - Nov 19, 2015
P1, N=20, Completed, Sponsor: Merck KGaA
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial primary completion date, Combination therapy, Metastases: EMR200592-006: Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer (clinicaltrials.gov) - Nov 11, 2015
P1, N=48, Recruiting, Sponsor: EMD Serono
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Sep 2015
- | evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
New P1 trial, Combination therapy: Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer. (clinicaltrials.gov) - Nov 8, 2015
P1, N=18, Not yet recruiting, Sponsor: Maastricht Radiation Oncology
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial primary completion date, Combination therapy, Metastases: EMR200592-008: A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 22, 2015
P2, N=46, Recruiting, Sponsor: Merck KGaA
Trial primary completion date: Jun 2016 --> Sep 2015 Trial primary completion date: Oct 2016 --> Jan 2017
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial primary completion date, Metastases: EMR200592-007: A Phase 1 TH-302 Mass Balance Trial (clinicaltrials.gov) - Aug 24, 2015
P1, N=10, Active, not recruiting, Sponsor: Merck KGaA
Trial primary completion date: Oct 2016 --> Jan 2017 Trial primary completion date: Jul 2015 --> Sep 2014
- || evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial primary completion date, Combination therapy, Metastases: Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 21, 2015
P2, N=440, Recruiting, Sponsor: Threshold Pharmaceuticals
Trial primary completion date: Jul 2015 --> Sep 2014 Trial primary completion date: Jul 2016 --> Oct 2017
- Avastin (bevacizumab) / Roche, evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial primary completion date: Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab (clinicaltrials.gov) - Aug 17, 2015
P2, N=34, Active, not recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
Trial primary completion date: Jul 2016 --> Oct 2017 Trial primary completion date: Jul 2015 --> Jul 2016
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial primary completion date, Surgery, Metastases: Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Aug 13, 2015
P1/2, N=48, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Jul 2015 --> Jul 2016 Trial primary completion date: Jan 2014 --> Jan 2016
- | evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Biomarker, Enrollment closed, Trial primary completion date, Metastases: A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma (clinicaltrials.gov) - Aug 11, 2015
P2, N=40, Active, not recruiting, Sponsor: Threshold Pharmaceuticals
Trial primary completion date: Jan 2014 --> Jan 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Sep 2016
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
New trial, Metastases: A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo (clinicaltrials.gov) - Jul 14, 2015
P=N/A, N=30, Suspended, Sponsor: University Health Network, Toronto
- Avastin (bevacizumab) / Roche, evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment open, Combination therapy: TH-302 in Combination With Bevacizumab for Glioblastoma (clinicaltrials.gov) - Jun 1, 2015
P2, N=33, Recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Sep 2016 Not yet recruiting --> Recruiting
- | evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
New P2 trial, Monotherapy, Metastases: Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer (clinicaltrials.gov) - May 5, 2015
P2, N=36, Recruiting, Sponsor: Seoul National University Hospital
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial primary completion date, Metastases: EMR200592-007: A Phase 1 TH-302 Mass Balance Trial (clinicaltrials.gov) - Apr 21, 2015
P1, N=10, Active, not recruiting, Sponsor: Merck KGaA
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2015 --> Jul 2015
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial primary completion date, Combination therapy, Monotherapy, IO biomarker, Metastases: EMR200592-002: A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer (clinicaltrials.gov) - Apr 21, 2015
P1, N=20, Active, not recruiting, Sponsor: Merck KGaA
Trial primary completion date: Mar 2015 --> Jul 2015 Trial primary completion date: Jan 2015 --> Oct 2015
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial primary completion date, Metastases: A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 14, 2015
P1, N=40, Recruiting, Sponsor: Threshold Pharmaceuticals
Trial primary completion date: Jan 2015 --> Oct 2015 Trial primary completion date: Jan 2015 --> Jul 2016
- | Sutent (sunitinib) / Pfizer, evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
New P2 trial, Combination therapy, Metastases: SUNEVO: A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours (clinicaltrials.gov) - Apr 2, 2015
P2, N=43, Recruiting, Sponsor: Grupo Espanol de Tumores Neuroendocrinos
- Avastin (bevacizumab) / Roche, evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment closed: Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab (clinicaltrials.gov) - Apr 1, 2015
P2, N=34, Active, not recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
Trial primary completion date: Jan 2015 --> Jul 2016 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
New P2 trial, Combination therapy: TH-302 in Combination With Bevacizumab for Glioblastoma (clinicaltrials.gov) - Jan 20, 2015
P2, N=33, Not yet recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
- ||||| evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment closed, Combination therapy, Metastases: MAESTRO: Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - Nov 6, 2014
P3, N=660, Active, not recruiting, Sponsor: EMD Serono
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Monotherapy, IO biomarker, Metastases: EMR200592-002: A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer (clinicaltrials.gov) - Oct 30, 2014
P1, N=20, Active, not recruiting, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=30 --> 20 | Trial primary completion date: Jul 2014 --> Jan 2015
- |||| evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial completion, Combination therapy, Metastases: Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma (clinicaltrials.gov) - Oct 30, 2014
P2, N=165, Completed, Sponsor: Threshold Pharmaceuticals
Recruiting --> Active, not recruiting | N=30 --> 20 | Trial primary completion date: Jul 2014 --> Jan 2015 Active, not recruiting --> Completed
- |||| evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial completion, Enrollment change, Combination therapy, Metastases: Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors (clinicaltrials.gov) - Oct 30, 2014
P1/2, N=71, Completed, Sponsor: Threshold Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=90 --> 71